Literature DB >> 2574230

Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

J Blin1, J C Baron, H Cambon, A M Bonnet, B Dubois, C Loc'h, B Mazière, Y Agid.   

Abstract

The dopamine D2 receptors were investigated in vivo in eight neuroleptic-free patients with persistent tardive dyskinesia using positron emission tomography and 76Br-bromospiperone. The striatal receptor density, estimated by the striatum/cerebellum radioligand concentration ratio, was not elevated in patients as compared with age-matched controls but was positively correlated with the severity of orofacial dyskinesia assessed with the Abnormal Involuntary Movement Rating Scale. These results indicate that tardive dyskinesia is associated with normal levels of striatal D2 receptors but the severity of orofacial movements may depend on the relative density of striatal D2 receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574230      PMCID: PMC1031632          DOI: 10.1136/jnnp.52.11.1248

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  Atlas of dopamine receptor images (PET) of the human brain.

Authors:  Y Inoue; H N Wagner; D F Wong; J M Links; J J Frost; R F Dannals; A E Rosenbaum; K Takeda; G Di Chiro; M J Kuhar
Journal:  J Comput Assist Tomogr       Date:  1985 Jan-Feb       Impact factor: 1.826

2.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

3.  GABA dysfunction in the pathophysiology of tardive dyskinesia.

Authors:  C A Tamminga; G K Thaker; T N Chase
Journal:  Psychopharmacology Suppl       Date:  1985

4.  Noradrenergic and neuroradiological abnormalities in tardive dyskinesia.

Authors:  C A Kaufmann; D V Jeste; R C Shelton; M Linnoila; M S Kafka; R J Wyatt
Journal:  Biol Psychiatry       Date:  1986-07       Impact factor: 13.382

5.  An international survey of tardive dyskinesia.

Authors:  W Guy; T A Ban; W H Wilson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1985       Impact factor: 5.067

6.  The Nithsdale schizophrenia survey. V. Follow-up of tardive dyskinesia at 3 1/2 years.

Authors:  A D Robinson; R G McCreadie
Journal:  Br J Psychiatry       Date:  1986-11       Impact factor: 9.319

7.  Behavioral effects of long-term neuroleptic treatment in Cebus monkeys.

Authors:  D E Casey
Journal:  Psychopharmacology Suppl       Date:  1985

8.  In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone.

Authors:  B Mazière; C Loc'h; J C Baron; P Sgouropoulos; N Duquesnoy; R D'Antona; H Cambon
Journal:  Eur J Pharmacol       Date:  1985-08-27       Impact factor: 4.432

9.  Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.

Authors:  P Jenner; N M Rupniak; C D Marsden
Journal:  Psychopharmacology Suppl       Date:  1985

10.  Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy.

Authors:  J C Baron; B Mazière; C Loc'h; H Cambon; P Sgouropoulos; A M Bonnet; Y Agid
Journal:  J Cereb Blood Flow Metab       Date:  1986-04       Impact factor: 6.200

View more
  10 in total

Review 1.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 2.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

5.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

7.  Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study.

Authors:  G P Reynolds; J E Brown; J C McCall; A V Mackay
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

9.  Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.

Authors:  H Karbe; K Wienhard; K Hamacher; M Huber; K Herholz; H H Coenen; G Stöcklin; A Lövenich; W D Heiss
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 10.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.